Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought forward more than a ...

Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

The Puerto Rico Science, Technology and Research Trust and the National Institute for Innovation in Manufacturing ...

Explore how nanomedicine and targeted therapies are shaping the future of cancer care in BCC Research’s global market analysis of nanotechnology in oncology.”Boston, June 05, 2025 (GLOBE NEWSWIRE) -- ...

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

In the midst of this inspiring evening, journalist Courtney Brown sat down with acclaimed actor Taye Diggs, who co-hosted the ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...